ArticleCase reports in medicine2026
Unusual Sequential Development of Multiple Sclerosis, Thymoma, Myasthenia, and Lymphoma in the Same Patient.
Article in Case reports in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unusual Sequential Development of Multiple Sclerosis, Thymoma, Myasthenia, and Lymphoma in the Same Patient.Case reports in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No case has yet been described in which a patient developed multiple sclerosis (MS) followed by thymoma, myasthenia gravis (MG), and T-cell lymphoma. The patient is a 47-year-old woman who developed relapsing-remitting MS at the age of 31 and was treated with interferon-beta (IFN-β) for over seven years. She was then diagnosed with thymoma, which was treated with chemotherapy and surgery. One year later, she was diagnosed with MG, which was treated with steroids, pyridostigmine, and intravenous immunoglobulins. Due to an MS relapse at the age of 40, ocrelizumab was administered for 2.5 years, after which she developed T-cell lymphoma. As the lymphoma had responded only partially to chemotherapy, an autologous stem cell transplantation was performed. It remains unclear whether there was a causal link between the immunosuppressive MS treatment and the thymoma or lymphoma, whether these developed due to underlying immune dysregulation, individual predisposition, or the cumulative effect of prior oncological therapies, or whether this was merely a chance co-occurrence of rare diseases. The case shows that a single patient may sequentially develop MS, MG, thymoma, and T-cell lymphoma. Fundamental and comprehensive clinical studies are required to elucidate the underlying pathophysiology and to confirm or refute a possible causal link.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.